{"doi":"10.1111/pcmr.13091","title":"<scp>B7‐H3</scp> drives immunosuppression and Co‐targeting with <scp>CD47</scp> is a new therapeutic strategy in β‐catenin activated melanomas","abstract":"In melanoma, immune cell infiltration into the tumor is associated with better patient outcomes and response to immunotherapy. T-cell non-inflamed tumors (cold tumors) are associated with tumor cell-intrinsic Wnt/β-catenin activation, and are typically resistant to anti-PD-1 alone or in combination with anti-CTLA-4 therapy. Reversal of the 'cold tumor' phenotype and identifying new effective immunotherapies are challenges. We sought to investigate the role of a newer immunotherapy agent, B7-H3, in this setting. RNA sequencing was used to identify co-targeting strategies upon B7-H3 inhibition in a well-defined preclinical melanoma model driven by β-catenin. We found that immune checkpoint molecule B7-H3 confers a suppressive tumor microenvironment by modulating antiviral signals and innate immunity. B7-H3 inhibition led to an inflamed microenvironment, up-regulation of CD47/SIRPa signaling, and together with blockade of the macrophage checkpoint CD47 resulted in additive antitumor responses. We found that the antitumor effects of the B7-H3/CD47 antibody combination were dependent on cytokine signaling pathways (CCR5/CCL5 and IL4).","journal":"Pigment Cell & Melanoma Research","year":2023,"id":371033,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":6,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9405,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":31291,"name":"Tiphaine Martin","orcid":"0000-0001-9990-1455","position":1,"is_corresponding":false},{"id":1002971,"name":"Nikki S. Vyas","orcid":"0000-0001-5026-1821","position":2,"is_corresponding":false},{"id":878847,"name":"Garrett Desman","orcid":"0000-0002-1557-300X","position":3,"is_corresponding":false},{"id":706893,"name":"Karen Mendelson","orcid":null,"position":4,"is_corresponding":false},{"id":485751,"name":"Basil A. Horst","orcid":null,"position":5,"is_corresponding":false},{"id":4789,"name":"Ramon Parsons","orcid":"0000-0002-6656-3514","position":6,"is_corresponding":false},{"id":570306,"name":"Jülide Tok Çelebi","orcid":"0000-0001-9926-3780","position":7,"is_corresponding":false},{"id":442739,"name":"Min Hsu","orcid":null,"position":0,"is_corresponding":true}],"reference_count":50,"raw_metadata":null,"created_at":"2026-07-19T01:15:45.330525Z","pmid":"37086018","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}